CagriSema

What CagriSema has been studied for

The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.

Weight loss (investigational)

In REDEFINE 1 (68 weeks, adults with overweight or obesity), the combination produced roughly 20% body-weight loss and outperformed semaglutide alone. The argument for it is a second, different appetite signal.

Weight loss with type 2 diabetes

Tested separately in REDEFINE 2 in people with type 2 diabetes, where weight loss is reliably smaller. The result was smaller than in REDEFINE 1, which matters when comparing headline numbers.

Blood pressure

Blood pressure fell alongside weight in REDEFINE 1. That is typical for this class rather than specific to this drug.

Mechanism of Action

How CagriSema works

CagriSema side effects: what studies reported

The same stomach complaints as semaglutide, in the same pattern: most frequent during dose escalation in the trials.

Dose-related findings. In REDEFINE 1, both components were escalated together over several weeks, and most gastrointestinal effects occurred in that period.

Source: REDEFINE phase 3 programme. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about CagriSema belong with a licensed clinician who knows your history.

The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.

Often discussed alongside

Compounds that come up next to CagriSema in research and discussion. Each has its own page. None of this is a suggestion to combine them.

Semaglutide

componentStrong Evidence

Semaglutide (GLP-1 Receptor Agonist)

A weekly injection sold as Ozempic for diabetes and Wegovy for weight loss. It is a rebuilt copy of a hormone your gut releases after eating, the one that tells your brain you are full, engineered to last a week instead of minutes. Its SELECT trial also showed fewer heart attacks and strokes in people with heart disease and obesity, which became an approved use for Wegovy.

4

Gene variants

200+

Studies

Cagrilintide

componentEmerging Evidence

Cagrilintide (Long-acting Amylin Analog)

A long-acting copy of amylin, a fullness hormone your pancreas releases alongside insulin that works through a completely different route from the GLP-1 drugs. It is mostly discussed as half of CagriSema, where it is paired with semaglutide so that two separate fullness signals are pushed at once.

3

Gene variants

12+

Studies

Access

Access and legal status

CagriSema: Investigational; under regulatory review. Decisions about any prescription medicine belong to a prescriber. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.

Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.

Worth knowing about CagriSema

Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.

Investigational, with no lawful consumer source

It is still in regulatory review, so there is no prescription route. Anything sold online under this name is not the tested product.

Stomach side effects are the common complaint

Nausea, constipation and reflux, most frequent during dose escalation in the trials. They are the main reason people stop drugs in this class.

It did not hit its own target

Novo aimed for 25% body-weight loss and landed around 20%. That is still a large number, larger than semaglutide alone, but the trial fell short of what was promised rather than beat it.

Weight comes back when you stop

As with every drug in this family studied so far, appetite returns to where it was after stopping, and so does the weight.

Frequently Asked Questions